Voyager Therapeutics Inc. (VYGR)
| Bid | 3.47 |
| Market Cap | 191.84M |
| Revenue (ttm) | 76.59M |
| Net Income (ttm) | -62.23M |
| EPS (ttm) | -1.13 |
| PE Ratio (ttm) | -3.08 |
| Forward PE | -3.71 |
| Analyst | Buy |
| Ask | 3.56 |
| Volume | 163,360 |
| Avg. Volume (20D) | 361,503 |
| Open | 3.63 |
| Previous Close | 3.65 |
| Day's Range | 3.46 - 3.64 |
| 52-Week Range | 3.46 - 10.66 |
| Beta | 0.99 |
About VYGR
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau...
Analyst Forecast
According to 8 analyst ratings, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 245.32% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call TranscriptVoyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CE...
